Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 2
1953 3
1954 1
1955 1
1956 6
1957 8
1958 14
1959 5
1961 3
1964 3
1967 6
1970 4
1971 1
1972 2
1973 3
1974 4
1975 7
1976 1
1977 1
1978 1
1979 3
1980 3
1981 1
1982 6
1983 5
1984 12
1985 12
1986 8
1987 5
1988 4
1989 24
1990 17
1991 8
1992 4
1993 9
1994 1
1995 7
1996 8
1997 14
1998 15
1999 18
2000 11
2001 11
2002 6
2003 5
2004 5
2005 2
2006 6
2007 9
2008 7
2009 5
2010 4
2011 3
2012 3
2013 4
2014 8
2015 9
2016 8
2017 7
2018 15
2019 17
2020 9
2021 10
2022 9
2023 14
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

433 results

Results by year

Filters applied: . Clear all
Page 1
Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials.
Kappos L, Wolinsky JS, Giovannoni G, Arnold DL, Wang Q, Bernasconi C, Model F, Koendgen H, Manfrini M, Belachew S, Hauser SL. Kappos L, et al. Among authors: bernasconi c. JAMA Neurol. 2020 Sep 1;77(9):1132-1140. doi: 10.1001/jamaneurol.2020.1568. JAMA Neurol. 2020. PMID: 32511687 Free PMC article. Clinical Trial.
Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials.
Bar-Or A, Thanei GA, Harp C, Bernasconi C, Bonati U, Cross AH, Fischer S, Gaetano L, Hauser SL, Hendricks R, Kappos L, Kuhle J, Leppert D, Model F, Sauter A, Koendgen H, Jia X, Herman AE. Bar-Or A, et al. Among authors: bernasconi c. EBioMedicine. 2023 Jul;93:104662. doi: 10.1016/j.ebiom.2023.104662. Epub 2023 Jun 22. EBioMedicine. 2023. PMID: 37354600 Free PMC article. Clinical Trial.
Metabolites in the regulatory risk assessment of pesticides in the EU.
Pelkonen O, Abass K, Parra Morte JM, Panzarea M, Testai E, Rudaz S, Louisse J, Gundert-Remy U, Wolterink G, Jean-Lou Cm D, Coecke S, Bernasconi C. Pelkonen O, et al. Among authors: bernasconi c. Front Toxicol. 2023 Dec 19;5:1304885. doi: 10.3389/ftox.2023.1304885. eCollection 2023. Front Toxicol. 2023. PMID: 38188093 Free PMC article. Review.
Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial.
Burmester GR, Buttgereit F, Bernasconi C, Álvaro-Gracia JM, Castro N, Dougados M, Gabay C, van Laar JM, Nebesky JM, Pethoe-Schramm A, Salvarani C, Donath MY, John MR; SEMIRA collaborators. Burmester GR, et al. Among authors: bernasconi c. Lancet. 2020 Jul 25;396(10246):267-276. doi: 10.1016/S0140-6736(20)30636-X. Lancet. 2020. PMID: 32711802 Clinical Trial.
Practical Aspects of Designing and Conducting Validation Studies Involving Multi-study Trials.
Coecke S, Bernasconi C, Bowe G, Bostroem AC, Burton J, Cole T, Fortaner S, Gouliarmou V, Gray A, Griesinger C, Louhimies S, Gyves EM, Joossens E, Prinz MJ, Milcamps A, Parissis N, Wilk-Zasadna I, Barroso J, Desprez B, Langezaal I, Liska R, Morath S, Reina V, Zorzoli C, Zuang V. Coecke S, et al. Among authors: bernasconi c. Adv Exp Med Biol. 2016;856:133-163. doi: 10.1007/978-3-319-33826-2_5. Adv Exp Med Biol. 2016. PMID: 27671721 Review.
Cytochrome P450 Induction and Xeno-Sensing Receptors Pregnane X Receptor, Constitutive Androstane Receptor, Aryl Hydrocarbon Receptor and Peroxisome Proliferator-Activated Receptor α at the Crossroads of Toxicokinetics and Toxicodynamics.
Hakkola J, Bernasconi C, Coecke S, Richert L, Andersson TB, Pelkonen O. Hakkola J, et al. Among authors: bernasconi c. Basic Clin Pharmacol Toxicol. 2018 Sep;123 Suppl 5:42-50. doi: 10.1111/bcpt.13004. Epub 2018 Apr 29. Basic Clin Pharmacol Toxicol. 2018. PMID: 29527807 Free article. Review.
A smartphone sensor-based digital outcome assessment of multiple sclerosis.
Montalban X, Graves J, Midaglia L, Mulero P, Julian L, Baker M, Schadrack J, Gossens C, Ganzetti M, Scotland A, Lipsmeier F, van Beek J, Bernasconi C, Belachew S, Lindemann M, Hauser SL. Montalban X, et al. Among authors: bernasconi c. Mult Scler. 2022 Apr;28(4):654-664. doi: 10.1177/13524585211028561. Epub 2021 Jul 14. Mult Scler. 2022. PMID: 34259588 Free PMC article.
433 results